Manufacturing

ROSS’s DCB-5 Double Cone Tumble Blender can handle high-density materials and provides repeatable homogeneity and powder blending properties, according to the company.

David Basile, VP Technical Operations, Americas, Hovione, highlights some common mistakes made by pharmaceutical companies when maintaining manufacturing facilities and equipment.

Pharmaceutical Technology®’s quality experts, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs company, and Siegfried Schmitt, PhD, vice president, Technical at Parexel discuss how pharmaceutical manufacturing training has evolved over the years and how the influx of new facilities is demanding a skilled workforce.

Life sciences is a decade behind other industries in its optimization and strategic exploitation of data. This is perplexing, given how much companies profess their ambitions to exploit AI. An industry podcast brought together life sciences thought leaders to debate the subject. The panelists noted that really, by now, standardized data should be yielding greater intelligence, and powering pharma’s future, accelerated by AI. If only companies could find new momentum to finally sort out their underlying data. This article sets out some of the key points that arose from the panel.

A new facility in Tennessee will boost high-speed pharma packaging capacity and strengthen US supply chain support.

The new Tethered Cap, which will be showcased at 2026 Pharmapack Europe, addresses the demand for sustainability with a TE safety ring that remains attached to the cap.

David Basile, VP Technical Operations, Americas, Hovione, explains what regulators expect for the maintenance of GMP facilities and equipment.

Luca Cavazzini, Sales & Marketing Director at IMA Active, discusses some of the industry’s most common manufacturing challenges, such as sustainability, continuous processes, and technology advancements.

Technology advances are converging with cost and time pressures and formulation complexity to drive greater adoption of automated processes.

The articles in this issue reflect an industry in transition, committed to innovation while ensuring safe, reliable, and forward-looking pharmaceutical production.

Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, outlines the importance of batch recovery procedures in pharmaceutical manufacturing.

Large-language models are excellent for general-use AI systems, but they don’t understand pharmaceutical companies’ proprietary documentation—the validated procedures and quality protocols that ensure drug safety. Smaller, domain-specific language models give companies more control and efficiency in their AI use.

Starting with risk mitigation, GMP facility and equipment maintenance is all about anticipating problems before they happen and showing regulators a controlled environment.

3D printing enables personalized precise drug delivery, enhances compounding efficiency, and is driving new regulatory models like distributed pharmaceutical manufacturing.

Webinar Date/Time: Tue, Dec 9, 2025 11:00 AM EST

Take our survey to voice your opinions on the bio/pharma industry impacts of the FDA Commissioner’s National Priority Vouchers program.

Webinar Date/Time: Thu, Nov 20, 2025 12:30 PM EST

Webinar Date/Time: Fri, Nov 21, 2025 11:00 AM EST

Pharma companies are focusing on sustainability efforts to meet client expectations, environmental audits, and climate pressures.

Sriman Banerjee of Takeda Pharmaceuticals says patient adherence is improving thanks to technologies that offer a more personalized approach.

SGD Pharma’s Najet Mebarki provides an overview of more than a half dozen services, products, and treatments, including ready-to-use solutions.

SK pharmteco boosts US peptide synthesis and purification capabilities, advancing reliable large-scale manufacturing for biopharma innovation.

Webinar Date/Time: Tue, Nov 18, 2025 11:00 AM EST

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.

At CPHI and AAPS, Ashland plans to detail the impacts of its advanced excipients: ultra-low nitrite materials curb nitrosamine risk, while high-purity sucrose stabilizes complex biologics.